Safety and efficacy of an ultrashort-acting β1-blocker on left ventricular dysfunction

Landiolol hydrochloride, an ultrashort-acting β1-selective blocker, is a highly regulated drug. This study evaluated the safety and efficacy of this drug for cases of coronary artery bypass grafting (CABG) with left ventricular dysfunction. Between September 2006 and August 2009, 32 patients with a...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The Heart surgery forum 2012-08, Vol.15 (4), p.E189-E194
Hauptverfasser:	Ito, Nobuhisa, Tashiro, Tadashi, Morishige, Noritsugu, Nishimi, Masaru, Hayashida, Yoshio, Minematsu, Noritoshi, Kuwahara, Go, Sukehiro, Yuta, Teratani, Hiromitsu
Format:	Artikel
Sprache:	eng
Schlagworte:	Adrenergic beta-Antagonists - administration & dosage Adrenergic beta-Antagonists - adverse effects Anti-Arrhythmia Agents - administration & dosage Anti-Arrhythmia Agents - adverse effects Atrial Fibrillation - etiology Atrial Fibrillation - prevention & control Coronary Artery Bypass - adverse effects Dose-Response Relationship, Drug Female Humans Male Middle Aged Morpholines - administration & dosage Morpholines - adverse effects Premedication Urea - administration & dosage Urea - adverse effects Urea - analogs & derivatives Ventricular Dysfunction, Left - chemically induced Ventricular Dysfunction, Left - diagnosis Ventricular Dysfunction, Left - prevention & control
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Landiolol hydrochloride, an ultrashort-acting β1-selective blocker, is a highly regulated drug. This study evaluated the safety and efficacy of this drug for cases of coronary artery bypass grafting (CABG) with left ventricular dysfunction. Between September 2006 and August 2009, 32 patients with a left ventricular ejection fraction of
ISSN:	1522-6662
DOI:	10.1532/HSF98.20111152